Abstract
Objective: The addition of heated intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery in the treatment of primary epithelial ovarian cancer (EOC) was associated with a 12-month overall survival (OS) benefit in a landmark randomized trial. There remains uncertainty in the literature about the clinical value and safety of HIPEC in ovarian cancer. The aim of this systematic review and meta-analysis was to assess oncologic outcomes and perioperative morbidity following HIPEC among patients with primary EOC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
